caa a22 4500 465789765 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00171985 doi (NATIONALLICENCE)springer-10.1007/BF00171985 Combination high-dose etoposide and vincristine infusion [Elektronische Daten] [Don Jackson Jr., Julia Cruz, Douglas White, Hyman Muss, Allen Chauvenet] Summary: Following the identification of a synergistic antitumor effect in a murine model, the combination of etoposide and vincristine has been explored in the clinic. Etoposide was given at 4 dose levels (250, 500, 750 or 1,000 mg/m2) with each dose given in 3 equal fractions daily for 3 days. The dose of vincristine was fixed (two 0.75 mg infusions over 22 hours each between doses of etoposide). A total of 26 patients were entered into study and 7, 11, 10 and 5 patients were treated at the 250, 500, 750, and 1,000 mg/m2 dose levels, respectively. Myelosuppressioh was the principle side effect and Grade 4 WBC toxicity (< 1,000/mm3) developed in 14%, 27%, 40% and 40%, respectively, of the patients treated at each of these respective dose levels. Life-threatening infections occurred in 0%, 9%, 30% and 60% of the patients at these levels, respectively. Reversal of marrow toxicity was rapid with repeat courses given at 3-week intervals. Non-hematologic toxicity, including neurotoxicity, nausea, vomiting, and mucositis was generally mild when present. Objective responses were observed in 1 patient each with refractory Hodgkin's disease and immunoblastic lymphoma. Prolonged periods of stable disease occurred in 2 patients with adenocarcinoma of the lung and one patient with Hodgkin's disease. The starting dose of etoposide recommended for further trials of this agent in combination with infusion of vincristine is 500 mg/m2 given in fractionated doses; dose escalation should be possible in many patients. Kluwer Academic Publishers, 1990 etoposide (VP-16) nationallicence vincristine nationallicence infusion nationallicence Jackson Jr. Don Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut Cruz Julia Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut White Douglas Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut Muss Hyman Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut Chauvenet Allen Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S59-S64 0167-6997 8<S59 1990 8 10637 https://doi.org/10.1007/BF00171985 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171985 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jackson Jr Don Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut NATIONALLICENCE 700 1- Cruz Julia Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut NATIONALLICENCE 700 1- White Douglas Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut NATIONALLICENCE 700 1- Muss Hyman Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut NATIONALLICENCE 700 1- Chauvenet Allen Cancer Center of Wake Forest University, 300 S. Hawthorne Road, 27103, Winston-Salem, NC, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S59-S64 0167-6997 8<S59 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer